Cargando…

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer

INTRODUCTION: Metastatic breast cancer (MBC) is a diverse disease. Therapeutic options include hormonal therapy, chemotherapy, and targeted therapies. The optimal treatment sequence for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancer remains unknown. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Mahmasani, Layal, Amhaz, Ghid, Abou Zeidane, Reine, Chamseddine, Nathalie, Hatab, Taha, Sabbagh, Saad, Charafeddine, Maya, Assi, Hazem I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619648/ https://www.ncbi.nlm.nih.gov/pubmed/37920158 http://dx.doi.org/10.3389/fonc.2023.1181375

Ejemplares similares

Breast cancer knowledge in Lebanese females with positive family history
por: El Maouchi, Paul, et al.
Publicado: (2023)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Latest updates on cellular and molecular biomarkers of gliomas
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Tumor Lysis Syndrome: A Rare Complication of Metastatic Gastric Cancer and a Possible Indicator of Disease Progression
por: Barakat, Salim, et al.
Publicado: (2022)

Immunotherapy in indolent Non-Hodgkin's Lymphoma
por: Amhaz, Ghid, et al.
Publicado: (2022)

Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
por: El Sayed, Rola, et al.
Publicado: (2021)

COVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications
por: Al Mahmasani, Layal, et al.
Publicado: (2021)

Emerging genetic biomarkers in lung adenocarcinoma
por: Barbar, Jawad, et al.
Publicado: (2022)

The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges
por: Bouferraa, Youssef, et al.
Publicado: (2021)

From Tumor Cells to Endothelium and Gut Microbiome: A Complex Interaction Favoring the Metastasis Cascade
por: Abdel Sater, Ali H., et al.
Publicado: (2022)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Primary Squamous Cell Carcinoma of the Liver: Case Report and Review of Literature
por: Fakhreddine, Omar, et al.
Publicado: (2022)

COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges
por: Moubarak, Simon, et al.
Publicado: (2022)

Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination
por: Atoui, Ali, et al.
Publicado: (2022)

Manifestation of paroxysmal nocturnal hemoglobinuria after COVID-19 mRNA vaccination
por: Jarrah, Kawthar, et al.
Publicado: (2022)

Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon
por: Atoui, Ali, et al.
Publicado: (2022)

Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates
por: Chedid, Julien, et al.
Publicado: (2022)

Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
por: El Sayed, Rola, et al.
Publicado: (2019)

Glioblastoma multiforme metastasizing to the skin, a case report and literature review
por: Nakib, Clara El, et al.
Publicado: (2021)

Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population
por: Saadeh, Fadi S., et al.
Publicado: (2020)

The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
por: Yang, Ziyan, et al.
Publicado: (2020)

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
por: Montagna, Emilia, et al.
Publicado: (2019)

Outcomes of Patients with Malignancy Admitted to the Intensive Care Units: A Prospective Study
por: Assi, Hazem I., et al.
Publicado: (2021)

Therapeutic Interventions in Adult Low-Grade Gliomas
por: Chammas, Majid, et al.
Publicado: (2019)

Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey
por: Lin, Peggy L., et al.
Publicado: (2015)

Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab
por: Maya, Yuka, et al.
Publicado: (2020)

A Survey on the Knowledge, Attitudes, and Practices of Lebanese Physicians Regarding Air Pollution
por: Assi, Hazem I., et al.
Publicado: (2022)

Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2010)

Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors
por: Weide, Rudolf, et al.
Publicado: (2014)

Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study
por: Mansfield, Carol, et al.
Publicado: (2022)

Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients
por: Assi, Hazem I., et al.
Publicado: (2020)

Clinical, genetic, and molecular characterization of hyperphosphatasia with mental retardation: a case report and literature review
por: Abi Farraj, Layal, et al.
Publicado: (2019)

Challenges Facing Viral Hepatitis C Elimination in Lebanon
por: Ayoub, Nour, et al.
Publicado: (2023)

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer
por: Redondo, Andrés, et al.
Publicado: (2014)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021)

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
por: Agrawal, Chaturbhuj, et al.
Publicado: (2021)

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
por: You, Shuhui, et al.
Publicado: (2023)

Testing the Kundera Hypothesis: Does Every Woman (But Not Every Man) Prefer Her Child to Her Mate?
por: Hernández Blasi, Carlos, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5unq8hfl1fh0eq8oidu5hl2as7